EU-Authorised Pertussis Booster Vaccination for Teenagers

Teenagers play an important role in the transmission dynamics of pertussis. As immunity acquired through early childhood vaccination gradually wanes, adolescents may become susceptible again. In this age group, pertussis infection can present with mild or non-specific symptoms, which may remain unrecognised while still allowing transmission to others.

BioNet has developed a pertussis-only booster vaccine that has received EU Marketing Authorisation for use in adolescents aged 12 years and above. This vaccine offers a targeted approach to booster immunisation. Clinical studies supporting regulatory approval have evaluated safety and immunogenicity in this population, demonstrating the induction of neutralising antibody responses with persistence observed over time.

Maintaining pertussis protection in adolescents may contribute not only to individual health but also to broader public health objectives, including indirect protection of infants, family members, and other vulnerable populations. A pertussis-only booster enables focused immunisation without additional antigens when these are not clinically indicated.

The availability of this EU-authorised option supports national immunisation programmes and provides healthcare professionals and families with an evidence-based approach to adolescent pertussis prevention, consistent with current scientific understanding and European regulatory standards.

Read the full news: VacPertagen Receives EU Approval